Cargando…
Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer
Prostate cancer (PCa) is the most common non-dermatologic cancer in the western countries in western countries. High-risk PCa accounts for 15% of the diagnosed cases. In this study, we compare the long-term survival outcomes of radical prostatectomy (RP), radiation therapy (RT), brachytherapy (BT),...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378991/ https://www.ncbi.nlm.nih.gov/pubmed/25578739 http://dx.doi.org/10.1038/srep07713 |
_version_ | 1782519521601388544 |
---|---|
author | Lei, Jun H. Liu, Liang R. Wei, Qiang Yan, Shi B. Song, Tu R. Lin, Fu S. Yang, Lu Cao, De H. Yuan, Hai C. Xue, Wen B. Lv, Xiao Cai, Ying C. Zeng, Hao Han, Ping |
author_facet | Lei, Jun H. Liu, Liang R. Wei, Qiang Yan, Shi B. Song, Tu R. Lin, Fu S. Yang, Lu Cao, De H. Yuan, Hai C. Xue, Wen B. Lv, Xiao Cai, Ying C. Zeng, Hao Han, Ping |
author_sort | Lei, Jun H. |
collection | PubMed |
description | Prostate cancer (PCa) is the most common non-dermatologic cancer in the western countries in western countries. High-risk PCa accounts for 15% of the diagnosed cases. In this study, we compare the long-term survival outcomes of radical prostatectomy (RP), radiation therapy (RT), brachytherapy (BT), androgen- deprivation therapy (ADT), and watchful waiting (WW) in high-risk prostate cancer (PCa). Overall, RP/(RT plus ADT) gave the best survival outcome in patients with high-risk PCa, whereas ADT/WW had the worst outcome. The overall priority for treatment strategy could be ranked as follows: RP/(RT plus ADT), RT, and ADT/WW. RP had significant better overall survival (OS) than RT or BT, and RP had significant lower cancer-specific mortality (CSM) than RT (0.51 [95% CI 0.30–0.73], P<0.001). ADT improved the cancer-specific survival (CSS) of RP based on a case-controlled study; added ADT to RT failed to challenge the position of RP but could improve the outcome of RT. In conclusions,RP/(RT plus adjuvant ADT) could both be used for the first-line therapy of high-risk PCa. When encountering an individual patient, urologists should consider various factors like tumors themselves, preferences of individuals, and so on. |
format | Online Article Text |
id | pubmed-5378991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53789912017-04-07 Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer Lei, Jun H. Liu, Liang R. Wei, Qiang Yan, Shi B. Song, Tu R. Lin, Fu S. Yang, Lu Cao, De H. Yuan, Hai C. Xue, Wen B. Lv, Xiao Cai, Ying C. Zeng, Hao Han, Ping Sci Rep Article Prostate cancer (PCa) is the most common non-dermatologic cancer in the western countries in western countries. High-risk PCa accounts for 15% of the diagnosed cases. In this study, we compare the long-term survival outcomes of radical prostatectomy (RP), radiation therapy (RT), brachytherapy (BT), androgen- deprivation therapy (ADT), and watchful waiting (WW) in high-risk prostate cancer (PCa). Overall, RP/(RT plus ADT) gave the best survival outcome in patients with high-risk PCa, whereas ADT/WW had the worst outcome. The overall priority for treatment strategy could be ranked as follows: RP/(RT plus ADT), RT, and ADT/WW. RP had significant better overall survival (OS) than RT or BT, and RP had significant lower cancer-specific mortality (CSM) than RT (0.51 [95% CI 0.30–0.73], P<0.001). ADT improved the cancer-specific survival (CSS) of RP based on a case-controlled study; added ADT to RT failed to challenge the position of RP but could improve the outcome of RT. In conclusions,RP/(RT plus adjuvant ADT) could both be used for the first-line therapy of high-risk PCa. When encountering an individual patient, urologists should consider various factors like tumors themselves, preferences of individuals, and so on. Nature Publishing Group 2015-01-12 /pmc/articles/PMC5378991/ /pubmed/25578739 http://dx.doi.org/10.1038/srep07713 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Lei, Jun H. Liu, Liang R. Wei, Qiang Yan, Shi B. Song, Tu R. Lin, Fu S. Yang, Lu Cao, De H. Yuan, Hai C. Xue, Wen B. Lv, Xiao Cai, Ying C. Zeng, Hao Han, Ping Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer |
title | Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer |
title_full | Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer |
title_fullStr | Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer |
title_full_unstemmed | Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer |
title_short | Systematic Review and Meta-analysis of the Survival Outcomes of First-line Treatment Options in High-risk Prostate Cancer |
title_sort | systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378991/ https://www.ncbi.nlm.nih.gov/pubmed/25578739 http://dx.doi.org/10.1038/srep07713 |
work_keys_str_mv | AT leijunh systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT liuliangr systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT weiqiang systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT yanshib systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT songtur systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT linfus systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT yanglu systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT caodeh systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT yuanhaic systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT xuewenb systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT lvxiao systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT caiyingc systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT zenghao systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer AT hanping systematicreviewandmetaanalysisofthesurvivaloutcomesoffirstlinetreatmentoptionsinhighriskprostatecancer |